Back to Trials
NCT00588068Recruiting

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

Memorial Sloan Kettering Cancer Center

Start Date

9/26/2000

Completion Date

9/1/2026

Summary

The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.

Detailed Description

To collect tumor, marrow specimens prospectively to study the molecular-genetic makeup of individual neuroblastic tumor and its metastasis by blood and marrow, and to correlate these findings with clinical outcome, and to relate the signaling circuitry of neuroblastic tumors to that of embryonic neuroectodermal cells. .

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: * Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System OR * Clinically suspected neuroblastic tumors. PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY): PK Draw Inclusion Criteria * Patients who receive naxitamab as part of their standard of care Exclusion Criteria: * None

Interventions

OTHER

Tumor and Marrow Markers

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Neuroblastoma

Locations

Memorial Sloan Kettering Cancer Center

New York, New York 10065

United States